Payment overview · 2025
General Payments
$214.33
12 reported records · 7 companies
Healthcare provider profile · identity verified
Herman Jackson Downey, MD
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, FL · NPI 1891772430
Verified facts
What the public records show
CMS Open Payments records show Herman Jackson Downey, MD received $214.33 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.05 | 24.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.58 | 23.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.33 | 17.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.94 | 11.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.63 | 8.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.55 | 8.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.25 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $214.33 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 825 | 244 |
| Atorvastatin Calcium | Atorvastatin Calcium | 797 | 226 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 624 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 476 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 401 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 374 | 95 |
| Valsartan | Valsartan | 318 | 91 |
| Gabapentin | Gabapentin | 305 | 101 |
| Losartan Potassium | Losartan Potassium | 275 | 77 |
| Montelukast Sodium | Montelukast Sodium | 249 | 75 |
| Telmisartan | Telmisartan | 246 | 66 |
| Lisinopril | Lisinopril | 239 | 68 |
| Famotidine | Famotidine | 237 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 56 |
| Omeprazole | Omeprazole | 176 | 55 |
| Spironolactone | Spironolactone | 169 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 44 |
| Trazodone Hcl | Trazodone Hcl | 137 | 40 |
| Jardiance | Empagliflozin | 127 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 121 | 41 |
| Carvedilol | Carvedilol | 120 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 35 |
| Farxiga | Dapagliflozin Propanediol | 112 | 29 |
| Metformin Hcl Er | Metformin Hcl | 107 | 32 |
| Mounjaro | Tirzepatide | 107 | 25 |
| Eliquis | Apixaban | 104 | 26 |
| Colestipol Hcl | Colestipol Hcl | 103 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 23 |
| Ozempic | Semaglutide | 88 | 27 |
| Metformin Hcl | Metformin Hcl | 85 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 24 |
| Buspirone Hcl | Buspirone Hcl | 84 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 80 | 22 |
| Synthroid | Levothyroxine Sodium | 80 | 16 |
| Allopurinol | Allopurinol | 76 | 23 |
| Atenolol | Atenolol | 75 | 21 |
| Alendronate Sodium | Alendronate Sodium | 71 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 22 |
| Rybelsus | Semaglutide | 68 | 17 |
| Azithromycin | Azithromycin | 63 | 59 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 19 |
| Memantine Hcl | Memantine Hcl | 59 | 14 |
| Nifedipine Er | Nifedipine | 58 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 48 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 16 |
| Trulicity | Dulaglutide | 48 | 13 |
| Prednisone | Prednisone | 47 | 41 |
| Verapamil Er | Verapamil Hcl | 46 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 39 | 12 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 16 |
| Donepezil Hcl | Donepezil Hcl | 34 | 11 |
| Mupirocin | Mupirocin | 33 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | 13 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 13 |
| Simvastatin | Simvastatin | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Verapamil Sr | Verapamil Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Belsomra | Suvorexant | 24 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Bydureon Bcise | Exenatide Microspheres | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Guanfacine Hcl | Guanfacine Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ramelteon | Ramelteon | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 19 |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Probenecid | Probenecid | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Colchicine | Colchicine | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Repatha Pushtronex | Evolocumab | 15 | suppressed |
| Zafirlukast | Zafirlukast | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | 11 |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $214.33 · 12 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, GARDASIL 9, GEMTESA, OFEV, Ozempic, Rybelsus, SHINGRIX, Veozah, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error